US$54 billion worth of biosimilar patents expiring before 2020

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

US$54 billion worth of biosimilar patents expiring before 2020

Biosimilars/Research | Posted 30/09/2011 0 Post your comment

By 2020 biological products with sales of around US$23 billion in the EU and US$29 billion in the US are expected to be exposed to biosimilar competition [1].

Obstacles with biosimilar entry timing are caused by the following facts:

There is no centralised listing of biological patents (like the Orange Book) and company analysis is kept confidential
Platform patents protect broad groups of products, e.g. humanised antibodies, which are not product specific
Each product has formulation patents which are difficult to assess

Estimated patent expiry dates for 12 major biological molecules are shown in Figure 1.

Figure 1: Expiry dates for patents on the 12 major biologicals

* EU provides 10 years of data exclusivity, US BPCI Act provides 12 years exclusivity
** In the UK. Other major EU markets follow on 28 August 2015.
*** Aqueous formulation patent runs until 2023, but dry powder biosimilar possible.
Source: Bernstein Research

For a high-resolution copy of Figure 1 please contact editorial@gabionline.net

Europe

European ‘composition of matter’ patents on Herceptin (trastuzumab), Remicaid (infliximab) and Rituxan (rituximab) will expire between November 2013 and July 2014, opening the way for biosimilar players.

Antibody biosimilars are expected to be introduced in Europe in the fourth quarter of 2013.

USA

The US market will open in the fourth quarter of 2013, with antibody biosimilars launching potentially in the fourth quarter of 2015 or early 2016.

Biosimilars for Epogen and Procrit (epoetin alfa) and Neupogen (filgrastim) are expected to enter the US market upon expiry of the ‘composition of matter’ patent in late 2013 as would ‘biobetters’ to Aranesp (darbepoetin alfa) and Neulesta (pegfilgrastim).

Other antibody products, such as Erbitux (cetuximab), Humira (adalimumab), Rituxan (rituximab), Synagis (palivizumab), will lose their ‘composition of matter’ patents and/or exclusivity protection in the fourth quarter of 2015 and early 2016. However, Roche’s Cabilly patent (platform patent) is expected to protect Rituxan until the end of 2018. After 2018, it is suspected that Roche will negotiate or barter the Cabilly patent rights to antibody markets it does not participate in.

This is a serious opportunity for biosimilar manufacturers. Almost US$54 billion of biological sales will be open to competition from biosimilars by 2010. No wonder that both generics manufacturers and Big Pharma, as well as biotech companies, are also vying for a piece of this lucrative pie [2].

Related articles

References

1. Gal R. Biosimilars: Reviewing US law and US/EU patents; bottom up model suggests 12 products and $7-$8B market by 2020. Bernstein Research. 26 May 2011.

2. GaBI Online - Generics and Biosimilars Initiative. Everybody jumping on the biosimilars bandwagon [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2011 September 30]. Available from: www.gabionline.net/Biosimilars/News/Everybody-jumping-on-the-biosimilars-bandwagon